97 related articles for article (PubMed ID: 26562960)
1. Pneumococcal Vaccines--a Real World Perspective.
Swaminathan S; Balajee G
J Assoc Physicians India; 2015 Apr; 63(4 Suppl):25-8. PubMed ID: 26562960
[No Abstract] [Full Text] [Related]
2. Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
Garattini L; Padula A; Da Costa MR
Pharmacoeconomics; 2016 Mar; 34(3):221-4. PubMed ID: 26518294
[No Abstract] [Full Text] [Related]
3. Commentary: Pneumococcal immunization may not be cost-effective in the elderly in developed countries.
Waugh N
Int J Epidemiol; 2005 Jun; 34(3):575-6. PubMed ID: 15764693
[No Abstract] [Full Text] [Related]
4. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
5. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
[TBL] [Abstract][Full Text] [Related]
6. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
Ortqvist A; Jönsson B; Baltussen R; Ament A
Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic.
Dhankhar P; Grabenstein JD; O'Brien MA; Dasbach EJ
Clin Ther; 2010 Aug; 32(8):1501-16. PubMed ID: 20728763
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
9. [Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].
Picazo JJ; González-Romo F; García Rojas A; Peréz-Trallero E; Gil Gregorio P; de la Cámara R; Morató ML; Rodríguez A; Barberán J; Domínguez Hernández V; Linares Rufo M; Jimeno Sanz I; Portolés JM; Sanz Herrero F; Espinosa Arranz J; García-Sánchez V; Galindo Izquierdo M
Rev Esp Quimioter; 2013 Sep; 26(3):232-52. PubMed ID: 24080892
[No Abstract] [Full Text] [Related]
10. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
[No Abstract] [Full Text] [Related]
11. [National economic consequences of vaccines].
Bergman A; Persson U
Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
[TBL] [Abstract][Full Text] [Related]
13. Vaccines: worth paying for the value returned.
Grabenstein JD
Ann Pharmacother; 2002 Sep; 36(9):1471-2. PubMed ID: 12229878
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Lucioni C; Mazzi S
Vaccine; 2006 Mar; 24(11):1735. PubMed ID: 16356601
[No Abstract] [Full Text] [Related]
15. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
16. Challenges in cost-effectiveness analyses of hospital interventions to improve quality.
Davis MM
Infect Control Hosp Epidemiol; 2008 May; 29(5):395-7. PubMed ID: 18419359
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
You JH; Wong WC; Ip M; Lee NL; Ho SC
J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal conjugate vaccine: are 3 doses equal to 4 doses?
Walter EB; Clements DA
Pediatrics; 2013 Aug; 132(2):e498-9. PubMed ID: 23821696
[No Abstract] [Full Text] [Related]
19. [Splenectomy and pneumococcal vaccination].
Postma MJ; Heijnen MA; de Vries R; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1141-2; author reply 1142. PubMed ID: 12822527
[No Abstract] [Full Text] [Related]
20. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
